TY - JOUR
T1 - Candida auris Clinical Isolates Associated with Outbreak in Neonatal Unit of Tertiary Academic Hospital, South Africa
AU - GERMS-SA
AU - Kekana, Dikeledi
AU - Naicker, Serisha D.
AU - Shuping, Liliwe
AU - Velaphi, Sithembiso
AU - Nakwa, Firdose L.
AU - Wadula, Jeannette
AU - Govender, Nelesh P.
AU - Black, John
AU - Pearce, Vanessa
AU - Moncho, Masego
AU - Maloba, Motlatji
AU - Hoosen, Anwar
AU - Verwey, Charl
AU - Charles, Feldman
AU - Menezes, Colin
AU - Moore, David
AU - Pombo, Dina
AU - Reubenson, Gary
AU - Ntlemo, Grace
AU - Nel, Jeremy
AU - Nchabeleng, Maphoshane
AU - Tsitsi, Merika
AU - Moshe, Moamokgethi
AU - Said, Mohammed
AU - du Plessis, Nicolette
AU - Chomba, Rispah
AU - Stacey, Sarah
AU - Avenant, Theunis
AU - Nana, Trusha
AU - Chibabhai, Vindana
AU - Maharj, Adhil
AU - Wilson, Douglas
AU - Naby, Fathima
AU - Dawood, Halima
AU - Han, Khine Swe Swe
AU - Sookan, Lisha
AU - Dlamini, Nomonde
AU - Ramjathan, Praksha
AU - Mahabeer, Prasha
AU - Bhola, Prathna
AU - Naidoo, Romola
AU - Haffejee, Sumayya
AU - Sirkar, Surendra
AU - Ramkillawan, Yeishna
AU - Hamese, Ken
AU - Sibiya, Ngoaka
AU - Mangena, Phetho
AU - Lekalakala, Ruth
AU - Hoyland, Greta
AU - Ntuli, Sindi
N1 - Publisher Copyright:
© 2023 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2023/10
Y1 - 2023/10
N2 - Candida auris was first detected at a university-affiliated hospital in Johannesburg, South Africa, in 2009. We used whole-genome sequencing to describe the molecular epidemiology of C. auris in the same hospital during 2016-2020; the neonatal unit had a persistent outbreak beginning in June 2019. Of 287 cases with culture-confirmed C. auris infection identified through laboratory surveillance, 207 (72%) had viable isolates and 188 (66%) were processed for whole-genome sequencing. Clade III (118/188, 63%) and IV (70/188, 37%) isolates co-circulated in the hospital. All 181/188 isolates that had a fluconazole MIC >32 µg/mL had ERG11 mutations; clade III isolates had VF125AL substitutions, and clade IV isolates had K177R/N335S/E343D substitutions. Dominated by clade III, the neonatal unit outbreak accounted for 32% (91/287) of all cases during the study period. The outbreak may have originated through transmission from infected or colonized patients, colonized healthcare workers, or contaminated equipment/environment.
AB - Candida auris was first detected at a university-affiliated hospital in Johannesburg, South Africa, in 2009. We used whole-genome sequencing to describe the molecular epidemiology of C. auris in the same hospital during 2016-2020; the neonatal unit had a persistent outbreak beginning in June 2019. Of 287 cases with culture-confirmed C. auris infection identified through laboratory surveillance, 207 (72%) had viable isolates and 188 (66%) were processed for whole-genome sequencing. Clade III (118/188, 63%) and IV (70/188, 37%) isolates co-circulated in the hospital. All 181/188 isolates that had a fluconazole MIC >32 µg/mL had ERG11 mutations; clade III isolates had VF125AL substitutions, and clade IV isolates had K177R/N335S/E343D substitutions. Dominated by clade III, the neonatal unit outbreak accounted for 32% (91/287) of all cases during the study period. The outbreak may have originated through transmission from infected or colonized patients, colonized healthcare workers, or contaminated equipment/environment.
UR - http://www.scopus.com/inward/record.url?scp=85171956236&partnerID=8YFLogxK
U2 - 10.3201/eid2910.230181
DO - 10.3201/eid2910.230181
M3 - Article
C2 - 37735719
AN - SCOPUS:85171956236
SN - 1080-6040
VL - 29
SP - 2044
EP - 2053
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 10
ER -